

Ajinomoto Bio-Pharma services announces its assets expansion

13 March 2019 | News | By Sonali Wankhade

Aji Bio-Pharma is also adding a new fully isolated, nested flexible fill line, installing automated packaging and labeling equipment, and upgrading its continuous flow and small molecule API manufacturing capabilities



Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading global company which is fully integrated contract development and manufacturing organization with sites in Belgium, United States, Japan, and India providing comprehensive development, cGMP manufacturing, and aseptic fill finish services for small and large molecule APIs and intermediates.

The company has provided an update on several of its capital projects currently underway in both the United States and Belgium. These projects total over \$100 Million and will further expand Aji Bio-Pharma's offerings and capabilities globally.

In addition to the previously announced highly potent product conjugation and fully isolated fill line which has recently commenced operations in its new state of the art facility in San Diego, Aji Bio-Pharma is also adding a new fully isolated, nested flexible fill line, installing automated packaging and labeling equipment, and upgrading its continuous flow and small molecule API manufacturing capabilities.